Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs).
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu QV, Torkelson A, Kirchmeier DR, Chutnik A, Pender BS, Sorror ML, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green DJ, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: cassaday rd. Blood Adv. 2024 Dec 3:bloodadvances.2024014455. doi: 10.1182/bloodadvances.2024014455. Online ahead of print. Blood Adv. 2024. PMID: 39626349
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Roloff GW, et al. Among authors: cassaday rd. J Clin Oncol. 2024 Oct 17:JCO2400321. doi: 10.1200/JCO.24.00321. Online ahead of print. J Clin Oncol. 2024. PMID: 39418622
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Aldoss I, et al. Among authors: cassaday rd. Blood Adv. 2024 Dec 10;8(23):6139-6147. doi: 10.1182/bloodadvances.2024013747. Blood Adv. 2024. PMID: 39093952 Free article.
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.
Kopmar NE, Othus M, Quach K, Rasmussen A, Schonhoff K, Becker PS, Walter RB, Halpern AB, Salit R, Cassaday RD, Shustov A, Stewart FM, Oehler VG, Scott BL, Sandmaier BM, Lee SJ, Estey EH, Percival MM. Kopmar NE, et al. Among authors: cassaday rd. Transplant Cell Ther. 2024 Jul;30(7):727.e1-727.e8. doi: 10.1016/j.jtct.2024.05.002. Epub 2024 May 5. Transplant Cell Ther. 2024. PMID: 38710302
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M. Krakow EF, et al. Among authors: cassaday rd. Blood. 2024 Sep 5;144(10):1069-1082. doi: 10.1182/blood.2024024105. Blood. 2024. PMID: 38683966 Clinical Trial.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y, Laird AD, Roberts KG, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Advani A, Mullighan CG. Zhao Y, et al. Among authors: cassaday rd. Blood Adv. 2024 Jun 25;8(12):3226-3236. doi: 10.1182/bloodadvances.2023012430. Blood Adv. 2024. PMID: 38607410 Free PMC article. Clinical Trial.
88 results